Core Viewpoint - Aquestive Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for Anaphylm™ (dibutepinephrine) Sublingual Film, which is intended for treating Type I allergic reactions, including anaphylaxis, in patients weighing 30kg or more [1][2] Group 1: FDA Response and Company Actions - The CRL highlighted deficiencies related to human factors in the Anaphylm validation study, specifically issues with pouch opening and film placement that could pose safety risks [2][3] - The company plans to modify the pouch design and labeling, and conduct a new human factors validation study to address the FDA's concerns [2][4] - No additional studies were requested by the FDA, and the company believes it can resolve the identified deficiencies quickly, aiming for resubmission in Q3 2026 [3][6] Group 2: Clinical Development and Market Strategy - The original NDA submission for Anaphylm is supported by a comprehensive clinical program involving 11 studies with approximately 967 administrations across 411 subjects, demonstrating a comparable pharmacokinetic profile to leading epinephrine auto-injectors [7][8] - The company is advancing its global expansion strategy for Anaphylm, with regulatory engagements initiated in Canada, Europe, and the UK, expecting to submit applications in the second half of 2026 [5][6] Group 3: Financial Position and Future Outlook - The company remains well-capitalized and anticipates ending 2026 with significant cash reserves, which will support the Anaphylm approval and pre-launch processes in the U.S. and other key markets [6][9] - The company is committed to bringing Anaphylm to the allergy community and believes in its potential as a non-invasive treatment option for severe allergic reactions [2][8]

Core Viewpoint - Aquestive Therapeutics is facing regulatory challenges with the FDA regarding its New Drug Application (NDA) for Anaphylm™, which has identified deficiencies that prevent discussions on labeling and post-marketing commitments, although the review is ongoing and no final decision has been made [2][6]. Regulatory Approval Status - The FDA has notified Aquestive of deficiencies in the NDA for Anaphylm, which the company is working to understand and resolve before the scheduled PDUFA action date of January 31, 2026 [2][3]. - The NDA submission for Anaphylm is supported by a comprehensive clinical development program, including eleven independent clinical studies with approximately 967 total administrations across 411 subjects [3]. Global Expansion Plans - Aquestive is advancing its global expansion strategy for Anaphylm, with plans to submit regulatory approvals in Canada, Europe, and the United Kingdom in 2026 [4][5]. - The company expects to submit its New Drug Submission (NDS) to Health Canada in the first half of 2026 and has received positive feedback from the European Medicines Agency (EMA) indicating no further clinical trials are needed prior to submission [4]. Financial Position - As of December 31, 2025, the company reported approximately $120 million in cash and cash equivalents, which is believed to be sufficient to support the approval and launch processes for Anaphylm in the U.S. and other key markets [6][7]. Product Overview - Anaphylm™ (dibutepinephrine) is a sublingual film designed to be easy-to-use, fast-acting, and portable, representing a significant advancement for individuals with severe allergies [2][8]. - The product is comparable in pharmacokinetic profile to leading epinephrine auto-injectors and has shown a safety profile similar to that of epinephrine [3].

Core Viewpoint - Aquestive Therapeutics is making strategic leadership changes to support the potential launch of Anaphylm™, a novel epinephrine product, and to enhance its development pipeline [1][2][4] Leadership Changes - Dr. Matthew Davis has been appointed as Chief Development Officer, bringing over 20 years of experience in drug development and medical leadership [2][3] - Dr. Gary Slatko returns as interim Chief Medical Officer, with over three decades of experience in regulatory science and drug safety [3] - Peter Boyd has been promoted to Chief People Officer, having led various functions within the company since 2013 [4][5] Product Development - Anaphylm™ (dibutepinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug candidate designed for the rescue treatment of severe allergic reactions [7] - If approved by the FDA, Anaphylm would be the first oral medication for anaphylaxis, with a unique delivery method that does not require water or swallowing [7] Company Overview - Aquestive Therapeutics focuses on advancing medicines through innovative science and delivery technologies, with a portfolio that includes four commercialized products [8] - The company collaborates with pharmaceutical firms to develop new molecules using proprietary technologies like PharmFilm® [8]

Core Insights - Aquestive Therapeutics, Inc. is hosting a live fireside chat on November 6, 2025, focusing on its product candidate Anaphylm™ (dibutepinephrine) Sublingual Film, discussing regulatory progress and commercial readiness [1][2] Company Overview - Aquestive Therapeutics is a pharmaceutical company dedicated to improving patients' lives through innovative science and delivery technologies, developing orally administered products to deliver complex molecules [5] - The company has four commercialized products marketed by its licensees globally and collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies like PharmFilm® [5] Product Details - Anaphylm™ (dibutepinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug that is designed to be administered without water or swallowing, making it user-friendly [4] - If approved by the FDA, Anaphylm would be the first oral medication for the rescue treatment of severe allergic reactions, including anaphylaxis, with its trade name conditionally approved [4]

Core Insights - Aquestive Therapeutics is advancing its product candidate Anaphylm™ (dibutepinephrine) sublingual film for the treatment of severe allergic reactions, including anaphylaxis, with multiple presentations scheduled at the 2025 ACAAI Annual Meeting [1][2] Company Overview - Aquestive Therapeutics focuses on innovative science and delivery technologies to improve patient lives through the development of orally administered products [4] - The company has four commercialized products and collaborates with other pharmaceutical companies to bring new molecules to market using proprietary technologies like PharmFilm® [4] Product Details - Anaphylm™ is a polymer matrix-based epinephrine prodrug that is small, lightweight, and dissolves on contact without the need for water or swallowing [3] - If approved by the FDA, Anaphylm would be the first oral medication for the rescue treatment of severe allergic reactions, with its trade name conditionally approved [3]

Core Viewpoint - Aquestive Therapeutics has received two additional U.S. patents for Anaphylm, extending its protection until at least 2037, which reinforces its position in the market for treating severe allergic reactions [1][2][7]. Patent Protection - The newly issued patents include U.S. patent number 12,427,121 and U.S. patent number 12,443,850, which cover the proprietary composition for Anaphylm, an epinephrine prodrug sublingual film [2][3]. - These patents are part of a broader intellectual property strategy that includes multiple pending and planned patent applications across various continents [2]. Product Overview - Anaphylm is designed as a device-free, sublingual film that offers a patient-friendly alternative to traditional epinephrine injections, addressing the fear of needles among patients [3][4]. - The product is small, lightweight, and begins to dissolve upon contact, requiring no water or swallowing for administration [4]. Regulatory Timeline - The Prescription Drug User Fee Act (PDUFA) target action date for Anaphylm is set for January 31, 2026, pending FDA approval [3][6]. Company Background - Aquestive Therapeutics focuses on advancing innovative medicines through proprietary technologies, including PharmFilm and Adrenaverse™, to improve patient care [5]. - The company has four commercialized products and collaborates with other pharmaceutical companies to bring new molecules to market [5].

Core Viewpoint - Aquestive Therapeutics has announced that the FDA has determined that an advisory committee meeting is not required for the approval of Anaphylm™ (dibutepinephrine) Sublingual Film, with a target action date set for January 31, 2026 [1][7]. Product Overview - Anaphylm has the potential to be the first FDA-approved, non-invasive, orally delivered epinephrine product for treating severe allergic reactions, including anaphylaxis [2][3]. - The product is designed as a thin, dissolvable film that is placed under the tongue, offering a device-free and needle-free option for patients at risk of severe allergic reactions [2][3]. - Anaphylm is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve upon contact, requiring no water or swallowing for administration [4]. Clinical Development - Eleven clinical studies have been completed, totaling 967 administrations (840 single-dose and 127 repeat-dose) for adults and children over 30 kg [3]. - The development program includes a novel trial for oral allergy syndrome, demonstrating Anaphylm's real-world effectiveness [3]. Company Positioning - The company is well-positioned for the launch of Anaphylm, supported by recent financing activities totaling $160 million, which will facilitate outreach to healthcare providers, caregivers, and patients post-FDA approval [3]. - Aquestive Therapeutics is focused on advancing medicines through innovative science and delivery technologies, with four commercialized products marketed globally [5].